keyboard_arrow_up

Hand, Foot and Mouth Disease Pipeline Review, H2 2015

Hand, Foot And Mouth Disease - Pipeline Review, H2 2015 report provides comprehensive information on the therapeutic development for Hand, Foot And Mouth Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hand, Foot And Mouth Disease and special features on late-stage and discontinued projects.

Companies Mentioned in this report are Chongqing Zhifei Biological Products Co., Ltd., CJ CheilJedang Corp., iQur Limited, Sentinext Therapeutics Sdn Bhd, Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited

Get a copy of this report http://bit.ly/1FimGTR . This is a premium report price at US$2000 for a single user PDF license

Scope

·         The report provides a snapshot of the global therapeutic landscape of Hand, Foot And Mouth Disease

·         The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

·         The report reviews key players involved in the therapeutics development for Hand, Foot And Mouth Disease and enlists all their major and minor projects

·         The report summarizes all the dormant and discontinued pipeline projects

·         A review of the Hand, Foot And Mouth Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

·         Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

·         A detailed assessment of monotherapy and combination therapy pipeline projects

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.